Previous 10 | Next 10 |
Based on encouraging sales to date, Horizon Therapeutics (NASDAQ: HZNP ) boosts its peak sales expectation for Krystexxa (pegloticase injection) to more than $1B from more than $750M. Sales growth in 2019 should be more than 25%. More news on: Horizon Therapeutics Public Limited Company,...
-- Increases KRYSTEXXA ® (pegloticase injection) Peak U.S. Annual Net Sales Expectations to More Than $1 Billion -- -- Increases Teprotumumab Peak U.S. Annual Net Sales Expectations to More Than $1 Billion -- -- Announces 79 Percent of Patients Achieved a Complete Response...
-- Seventy-Nine Percent of Patients Achieved a Complete Response -- -- New Data Continues to Support Immunomodulation Strategy to Improve Patient Outcomes -- Horizon Therapeutics plc (Nasdaq: HZNP) announced today topline results from its MIRROR open-label study in which methotrex...
Today, we will be studying why Horizon Therapeutics ( HZNP ) is an attractive investment for 2020. Company overview Today, Horizon Therapeutics stands at the cusp of a major transformation. Once known mainly for its primary care drugs, the company has emerged as a leading rare disease bi...
Agilent (NYSE: A ) initiated with Overweight rating and $100 (18% upside) price target at Wells Fargo. More news on: Agilent Technologies, Inc., Avantor, Inc., Axonics Modulation Technologies, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Shares of Horizon Therapeutics (NASDAQ: HZNP) closed more than 4% higher on Monday after an U.S. Food and Drug Administration advisory committee voted in support of the company's treatment for thyroid eye disease, and the stock extended gains by more than 2% over the next two tradi...
Thinly traded nano cap Acer Therapeutics (NASDAQ: ACER ) is up 18% after hours in reaction to its announcement of full enrollment in Part B of a pivotal study evaluating candidate ACER-001 (sodium phenylbutyrate) for the treatment of urea cycle disorders. More news on: Acer T...
-- If approved, teprotumumab would be the first and only approved medicine for people living with TED, fulfilling a significant unmet need -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the U.S. Food a...
The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted 12-0 that the benefits of Horizon Therapeutics' (NASDAQ: HZNP ) teprotumumab outweigh the risks for the treatment of thyroid eye disease (TED). More news on: Horizon Therapeutics Public Limited Company, Healthcare stocks ...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that NASDAQ has halted trading of the Company’s common stock. As per the U.S. Food and Drug Administration (FDA) guidelines for new molecular entities (NMEs), the FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) is...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...